Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 280.00 GBp
Change Today +1.50 / 0.54%
Volume 29.0K
As of 12:35 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

silence therapeutics plc (SLN) Snapshot

Open
273.25 GBp
Previous Close
278.50 GBp
Day High
280.00 GBp
Day Low
273.00 GBp
52 Week High
04/1/14 - 320.25 GBp
52 Week Low
10/16/14 - 168.00 GBp
Market Cap
145.9M
Average Volume 10 Days
72.5K
EPS TTM
-0.23 GBp
Shares Outstanding
52.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SILENCE THERAPEUTICS PLC (SLN)

Related News

No related news articles were found.

silence therapeutics plc (SLN) Related Businessweek News

No Related Businessweek News Found

silence therapeutics plc (SLN) Details

Silence Therapeutics plc, a biotechnology company, discovers, develops, and delivers RNA interference (RNAi) therapeutics for the treatment of serious diseases primarily in North America and the Asia/Pacific. It has AtuRNAi, an RNAi platform, which encompasses the generation of potent chemically stabilized siRNA molecules. The company also has proprietary siRNA delivery technology platforms that comprise AtuPLEX, which delivers siRNA to the endothelial cells of the vascular system; DACC delivery system that delivers siRNA to the vascular endothelial cells of the lung; and DBTC delivery system, which delivers siRNA to hepatocytes and the hepatic vascular system of the liver parenchyma. Its products include Atu027, which is in the Phase IIa clinical trial for the treatment of pancreatic cancer, as well as in the Phase Ib clinical trial for head and neck cancer; Atu111 that is in pre-clinical stage for the treatment of lung diseases; and Atu112, which is in the pre-clinical stage for the treatment of systemic disorders. The company is also developing products for immunotherapy. Silence Therapeutics plc has partnership and collaboration agreements with various pharmaceutical companies, including Pfizer/Quark Pharmaceuticals, Novartis, AstraZeneca, Dainippon Sumitomo Pharma Co., Ltd., InteRNA Technologies B.V., Mirna Therapeutics Inc., and miRagen Therapeutics, Inc. The company was incorporated in 1994 and is based in London, the United Kingdom.

38 Employees
Last Reported Date: 06/4/14
Founded in 1994

silence therapeutics plc (SLN) Top Compensated Officers

Chief Executive and Director
Total Annual Compensation: 70.0K GBP
Finance Director, Company Secretary and Direc...
Total Annual Compensation: 119.0K GBP
Chief Operating Officer
Total Annual Compensation: 58.0K GBP
Chief Medical Officer and Director
Total Annual Compensation: 53.0K GBP
Compensation as of Fiscal Year 2013.

silence therapeutics plc (SLN) Key Developments

Silence Therapeutics plc Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 through Mar-04-2015

Silence Therapeutics plc Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 through Mar-04-2015. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Presentation Date & Speakers: Mar-03-2015, Michael Khan, Chief Medical Officer and Director.

Silence Therapeutics plc Announces Board Changes

Silence Therapeutics plc announced that Simon Sturge and Alastair Riddell will exchange roles. As from the January 5, 2015 Alastair Riddell will take on the role of Non-executive Chairman of the Board and Chair the Nominations Committee. Simon Sturge will remain a Non Executive Director and Chair the Remuneration Committee. Simon Sturge became Non-executive Chairman in November 2013. In March 2014 he was appointed to a senior executive role with Merck KgaA based in Switzerland heading their Biosimilars activity, which has necessarily reduced his availability in UK.

Silence Therapeutics plc Appoints Lars Karlsson as Head of Research and Development and as an Executive Director Effective January 5, 2015

Silence Therapeutics plc has appointed Dr. Lars Karlsson as Head of Research and Development from January 05, 2015. He will also join the board as an executive director. He joins Silence from Novo Nordisk where he was the Vice President for Auto-Immune Disease Pharmacology, responsible for all inflammatory research within Denmark.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SLN:LN 280.00 GBp +1.50

SLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alnylam Pharmaceuticals Inc $99.64 USD -2.14
Benitec Biopharma Ltd A$0.78 AUD +0.03
Isis Pharmaceuticals Inc $61.15 USD -1.24
Marina Biotech Inc $0.59 USD -0.01
View Industry Companies
 

Industry Analysis

SLN

Industry Average

Valuation SLN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,423.4x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,517.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SILENCE THERAPEUTICS PLC, please visit www.silence-therapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.